Grigorios Siokas Purchases 55,732 Shares of Cosmos Health (NASDAQ:COSM) Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas acquired 55,732 shares of Cosmos Health stock in a transaction dated Tuesday, November 25th. The stock was purchased at an average price of $0.63 per share, with a total value of $35,111.16. Following the completion of the purchase, the chief executive officer owned 6,383,625 shares of the company’s stock, valued at approximately $4,021,683.75. The trade was a 0.88% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Grigorios Siokas also recently made the following trade(s):

• On Friday, November 21st, Grigorios Siokas bought 56,080 shares of Cosmos Health stock. The stock was purchased at an average price of $0.68 per share, for a total transaction of $38,134.40.
• On Thursday, November 20th, Grigorios Siokas purchased 51,315 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.62 per share, with a total value of $31,815.30.
• On Wednesday, November 19th, Grigorios Siokas acquired 61,614 shares of Cosmos Health stock. The shares were acquired at an average price of $0.65 per share, with a total value of $40,049.10.

Cosmos Health Stock Performance

COSM stock traded up $0.01 during trading on Wednesday, hitting $0.64. 644,960 shares of the company traded hands, compared to its average volume of 611,960. The company has a market cap of $22.38 million, a PE ratio of -0.85 and a beta of 5.32. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.99 and a quick ratio of 0.84. The stock’s 50-day simple moving average is $0.92 and its 200 day simple moving average is $0.72. Cosmos Health Inc. has a 1 year low of $0.28 and a 1 year high of $1.32.

Cosmos Health (NASDAQ:COSM) last posted its earnings results on Friday, November 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.16). The firm had revenue of $17.11 million for the quarter, compared to analysts’ expectations of $16.40 million. Cosmos Health had a negative return on equity of 33.19% and a negative net margin of 31.01%. On average, equities analysts expect that Cosmos Health Inc. will post -0.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cosmos Health in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Cosmos Health to a “hold” rating in a report on Saturday, September 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Investors Weigh In On Cosmos Health

A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC raised its holdings in shares of Cosmos Health Inc. (NASDAQ:COSM) by 133.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 225,507 shares of the company’s stock after buying an additional 128,776 shares during the quarter. Citadel Advisors LLC owned about 0.65% of Cosmos Health worth $250,000 as of its most recent SEC filing. Institutional investors own 12.61% of the company’s stock.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names.